Did You Know...
...that the Slinky toy was the result of a failed attempt by engineer Richard James to produce an antivibration device for ship instruments? His goal was to develop a spring that would instantaneously counterbalance the wave motion that rocks a ship at sea. Instead, he developed the Slinky.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178546 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 2,5-Diaryl-1,2,4-triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase Type 1 enzyme (11β-HSD-1). The compounds are useful for the treatment of diabetes, hyperglycemia, obesity, insulin resistance, atheroscle... | 05/15/2012 |
| 8168646 | 3,4-dihydroquinazoline derivatives Disclosed are 3,4-dihydroquinazoline derivatives of formula (I), a process of preparing them and a pharmaceutical composition including them. The 3,4-dihydroquinazoline derivatives of the present invention have excellent T-type calcium channel blocking effect and an... | 05/01/2012 |
| 8093258 | Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatm... | 01/10/2012 |
| 8088782 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and proc... | 01/03/2012 |
| 8063055 | Substituted pyridone compounds and methods of use The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The... | 11/22/2011 |
| 8048888 | Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and EGFR inhibitors or pyrimidine analogues The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemoth... | 11/01/2011 |
| 8044063 | Quinazoline derivatives useful as anti-tumor medicament The present invention relates to quinazoline derivatives of the formula (I) useful as anti-tumor medicaments, or a pharmaceutically acceptable salt thereof, the definition of the substituents R1, R1′, R2, R2′ are as de... | 10/25/2011 |
| 7989463 | Biccyclic compounds as GATA modulators Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of... | 08/02/2011 |
| 7985755 | 2,4-diaminoquinazolines for spinal muscular atrophy 2,4-Diaminoquinazolines of formula (I) are provided herein and are useful for treating spinal muscular atrophy (SMA). ... | 07/26/2011 |
| 7977347 | Quinazoline based EGFR inhibitors The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR... | 07/12/2011 |
| 7947696 | 2-amino-4-phenylquinazoline derivatives and the use thereof as HSP90 modulators Novel phenylquinazoline derivatives of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for ... | 05/24/2011 |
| 7939540 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives A compound represented by the following formula (I), salt thereof, or hydrate thereof, can effectively relieve itch caused by atopic disease or the like: wherein R represents hydroxyl, C1-6 alkoxy optionally subs... | 05/10/2011 |
| 7932262 | Quinazolines for PDK1 inhibition The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. ... | 04/26/2011 |
| 7932261 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) The present invention is directed to macrocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β... | 04/26/2011 |
| 7906522 | 2-aminoquinazoline derivatives The present invention provides 2-aminoquinazoline derivatives represented by formula (I): wherein R1 and R2 may be the same or different and each represents a hydrogen atom, su... | 03/15/2011 |
| 7888366 | 2,4-diaminoquinazolines for spinal muscular atrophy 2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA). ... | 02/15/2011 |
| 7846938 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below. These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK... | 12/07/2010 |
| 7820683 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by ... | 10/26/2010 |
| 7790732 | 5-Chloro-4-alkyl-3,4-dihydro-quinazolin-2-ylamine derivatives The present invention relates to compounds of formula I wherein R1, R2, R3 are as described in the specification and pharmaceutically acceptable acid addition salts and tautomers t... | 09/07/2010 |
| 7790733 | 8-alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines The present invention relates to compounds of formula wherein R1, R2, R3, and n are as described in the specification and pharmaceutically acceptable acid addition salts ... | 09/07/2010 |
| 7781441 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine The present invention relates to compounds of formula I wherein R, R1, R2, R3, R4, aryl, n, and m are as defined in the specification and pharma... | 08/24/2010 |
| 7754729 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase a... | 07/13/2010 |
| 7700608 | Quinazoline derivatives and their use in the treatment of thrombocythemia A method for the treatment of thrombocythemia in a subject comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or equilibrating forms thereof. ... | 04/20/2010 |
| 7625911 | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their... | 12/01/2009 |
| 7544691 | Guanidine derivatives The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic dru... | 06/09/2009 |
| 7521456 | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazoli... | 04/21/2009 |
| 7504409 | Mucin synthesis inhibitors The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronc... | 03/17/2009 |
| 7456189 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation Compounds of the formula having an inhibitory action on the signal transduction mediated by tyrosine kinases, and being useful for the treatment of oncoses and of benign prostate hyperplasia (BPH), of diseases of the lung a... | 11/25/2008 |
| 7432275 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor act... | 10/07/2008 |
| 7429597 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions The present invention relates to new substituted nitrogen-containing heterobicyclic compounds of general formula wherein B, X1 to X3 and R1 to R5 are defined as in claim 1,... | 09/30/2008 |
| 7410975 | Small molecule toll-like receptor (TLR) antagonists The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are... | 08/12/2008 |
| 7388014 | Quinazoline derivatives and therapeutic use thereof Quinazoline derivatives represented by the general formula pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperprolifer... | 06/17/2008 |
| 7368454 | (3,4-dihydro-quinazolin-2-yl)-aryl-amines The present invention relates to methods for treating 5-HT5A receptor related diseases which comprises administering compounds of formula I wherein R1, R2,... | 05/06/2008 |
| 7365096 | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a der... | 04/29/2008 |
| 7358222 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 04/15/2008 |
| 7348333 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists There are described cycloalkyl derivatives of the formula (I) R1—Y-A-B-D-E-F-G (I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds a... | 03/25/2008 |
| 7348332 | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines The present invention relates to compounds of formula wherein R1, R2, and n are as defined herein and to pharmaceutically acceptable acid addition salts thereof. | 03/25/2008 |
| 7323472 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of inflammation enhanced cough in a mammal in need thereof. ... | 01/29/2008 |
| 7317019 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid a... | 01/08/2008 |
| 7314880 | Cardioprotective delta opioid receptor agonists and methods of using same The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce ... | 01/01/2008 |
